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Abstrac t
The  synthes es  and  transform a t ions  of  4-hydroxyquinoline- 2-carboxylic  acid,
kynurenic  acid,  are  reviewed,  and  special  attent ion  is  paid  to  the
pharm acological  activities  and  pharm ac e u t ical  applica tions  of  its  derivatives.
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1.  Introd u c t i o n
4-Hydroxyquinoline- 2-carboxyxlic  acid,  also  known  as  kynurenic  acid
(KYNA,  Fig.  1),  is  an  endogenous  product  of  the  tryptophan  (TRP)  metabolism,  a
pathway  (Fig.  2)  known  to  be  responsible  for  the  produc tion  of  nicotinamide
adenine  dinucleotide  (NAD + ) and  NAD  phospha te  (NADP + ) [1,2].  In  this  pathw ay,
TRP  is  conver t ed  into  various  compounds ,  including  L-kynurenine  (L-KYN),
which  can  be  metabolized  in  two  separa t e  ways,  one  branch  furnishing  KYNA,
and  the  other  3-hydroxykynure nine  (3-OH- KYN)  and  quinolinic  acid  (QUIN),  the





Among  the  import an t  featu re s  of  KYNA is  the  fact  that  it  is  one  of  the  few
known  endogenous  excitato ry  amino  acid  recepto r  blockers  with  a  broad
spect ru m  of  antagonis tic  proper t i es  in  supraphysiological  concen t r a t ions .  One  of
its  recently  confirmed  sites  of  action  is  the    - 7-nicotinic  acetylcholine  (   - 7-nACh)
recep to r  and,  interes t ingly,  a  more  recen tly  identified  one  is  a  higher- affinity
positive  modula to ry  binding  site  at  the  - amino- 3-hydroxy- 5-methyl- 4-α







































































Since  KYNA  is  a  TRP  metabolite  produced  by  astrocytes  and  neurons  via
the  KYN  pathway  in  both  humans  and  roden ts  [6-9],  and  since  it  is  an
endogenous  neurop ro te c t ive  agent  able  to  preven t  neuronal  loss  following
excitotoxic,  ischemia- induced  and  infectious  neuronal  injuries  [10,11],  there  has
recently  been  increasing  interes t  in  the  synthesis  and  pharm acological  studies  of
KYNA derivatives .
The  primary  aim  of  the  presen t  review  is  to  survey  the  methods  available
for  the  synthesis  and  transforma t ions  of  KYNA  derivatives.  Additionally,  the
pharm acological  activities  of  these  derivatives  will  be  reviewed.
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2.  Synth e s e s  and  transfor m a t i o n s  of  KYNA  derivative s
2.1.  Synth e s e s  of  KYNA  derivat ive s
The  general  procedu r e  for  the  synthesis  of  4-hydroxyquinolinic  acid
involves  a  modified  Conrad- Limpach  method,  star ting  from  the  commercially
available  substi tu t ed  arylamines  1 .  The  first  step  comprise s  enamine  bond
formation  through  the  use  of  dimethyl  acetylenedica rboxyla te  (DMAD)  or  diethyl































Sche m e  1.  Reagen t s  and  conditions:  i),  ii) see  Table  1;  iii) NaOH,  MeOH,  H 2O ,
rt;  then  HCl  (aq)
The  interme dia t e  fumara t e s  2a- m  are  then  cyclized  by  using  diphenyl
ether  or  Downthe r m  at  high  tempera t u r e ,  yielding  methyl  4-hydroxy- 2-
carboxylates  (3a- e  and  3i- m )  or  ethyl  4-hydroxy- 2-carboxylates  (3f- h ),
respec t ively.  The  reaction  conditions  for  the  prepa ra t ion  of  differen t  substi tu te d
4-hydroxyquinolinic  acid  derivatives  are  listed  in  Table  1.  For  3a- m , the  enol- oxo
tautome r is m  is  possible.  This  equilibrium  is  shifted  in  favor  of  the  oxo  form  when
C-2  contains  an  ester  function  (3a- m ),  while  the  presenc e  of  a  carboxylic  group
at  C-2  (4a- m ) favors  the  enol  form  (Scheme  1).
For  the  transforma t ions  of  the  4-hydroxy- quinoline  derivatives,  the  free
acids  (KYNA  derivatives)  are  needed.  Hydrolysis  of  the  ester s  is  genera lly
perform ed  in  methanolic  alkaline  medium  followed  by  acidification  with  HCl
(Schem e  1).
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Table  1.  Reagen t s  and  conditions  for  the  synthesis  of  KYNA derivatives  3a- m
Compoun
ds X Y R
Reaction  conditions
Referencesi
1   → 2
ii
2   3→
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2.2.  Transfor m a t i o n s  of  KYNA  derivative s
The  transform a t ions  of  KYNA  derivatives  can  be  achieved  in  differen t
ways:  transform a t ion  of  the  synthe t ically  active  4-OH  group,  and  conversion  of
the  2-carboxylic  function  to  the  pharm acologically  interes t ing  ester  or  amide
derivatives  of  KYNA.
2.2.1 .  Transfor m a t i o n s  of  the  hydroxy  group  at  posi t io n  4
The  4-OH  group  can  be  chlorinat e d  by  refluxing  the  star ting  mater ials  3a
and  3b  in  POCl 3  for  some  hours  [14],  resul ting  in  5  and  6 .  A new  approach  in
this  area  is  the  use  of  P 2O 5/Bu 4NBr  as  bromina ting  agent ,  furnishing  7  (Scheme
2)  [20].
The  reactions  of  3a  and  3i  with  benzyl  bromide  (BnBr)  in  basic  medium
(K2CO 3),  followed  by  hydrolysis  of  the  ester  moiety  with  NaOH,  led  to  O-
protect e d  acid  derivatives  8  [21,22]  and  9  [19],  respec t ively.  When  ethyl
bromide  was  applied  under  similar  reaction  conditions ,  the  OH  group  in  3b- 3d
was  transform e d  to  an  OEt  group  (10- 12 , Scheme  2)  [14].
On  the  use  of  methyl  bromoace t a t e  in  the  presence  of  NaH  in  DMF,  an
ether  moiety  containing  an  additional  ester  function  was  incorpora t e d  at  C-4  to
yield  13 , hydrolysis  of  which  led  to  dicarboxylic  acid  14  (Scheme  2)  [17].
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Y=,Z=H, R=Me: 3a
Y=6-F, Z=H, R=Me: 3b
Y=H, Z=OMe, R=Me: 3c
Y,Z=6,7-OCH2O, R=Me: 3d
Y=5-Cl, Z=Cl, R=Me: 3e















X=Cl, Y=Z=H, R=Me: 5
X=Cl, Y=6-F, ,Z=H, R=Me: 6








Y=6-F, Z=H, R=Me: 10




















Sch e m e  2.  Reagen t s  and  conditions:  i) POCl 3, reflux,  4  h;  ii) P 2O 5/Bu 4NBr,  100
°C,  toluene;  iii) BnBr,  K2CO 3 , DMF  then  NaOH,  H 2O,  MeOH;  iv ) K2CO 3 , EtBr,
DMF;  v ) methyl  bromoace t a t e ,  NaH,  DMF;  vi ) 1.0  M  LiOH,  MeOH
A series  of  KYNA derivatives  bearing  an  amide  moiety  at  C-4  ( 21- 23 ) have
been  prepa r e d  through  transform a t ion  of  the  OH  group  to  NH 2  by  refluxing  3f- h
with  chlorosulfonyl  isocyana t e ,  followed  by  the  coupling  of  15- 17  with
diphenylcarb a m oyl  chloride  in  the  presence  of  NaH.  The  hydrolysis  of  18- 20
10%  NaOH  and  then  HCl  (aq)  led  to  the  desired  substi tu t ed  KYNA  derivatives
21- 23  (Schem e  2)  [18].
27 , the  nitrogen- bridged  analog  of  14 , was  prepa re d  via  the  reaction  of  3e
with  p -tolylsulfonyl  isocyana te ,  which  resulted  in  24 .  Substi tu t ion  of  24  with
methyl  bromoace t a t e  and  subseque n t  hydrolysis  of  the  dimethyl  ester  gave  the
desired  dicarboxylic  acid  27  [17,23,24].
The  heating  of  24  with  MeI  in  the  presenc e  of  Na 2CO 3  yielded  methyl  4-


































































Sche m e  3.  Reagen t s  and  conditions:  i) chlorosulfonyl  isocyana t e ,    ,  MeCN;  ii)
diphenylca rba m oyl  chloride,  NaH,  0  °C,  DMF;  iii) 10%  NaOH  (aq)  then  HCl  (aq);
iv ) p -tolylsulfonyl  isocyana te ,    ,  MeCN;  v ) methyl  bromoace t a t e ,  NaH,  DMF;  vi )
90%  H 2SO 4, 0  °C;  vii ) MeI,  Na 2CO 3 , reflux,  MeCN  
2.2.2 .  Transfor m a t i o n s  of  the  ester /c arb oxyl i c  funct i o n  at  posi t io n  2
KYNA  derivatives  are  potent  NMDA  recepto r  antagonis t s ,  but  they  exert
only  weak  activity  after  systemic  administ r a t ion.  In  order  to  overcome  the  blood-
brain  barrier  (BBB),  new  ester s  that  are  actively  transpor t ed  across  the  BBB
have  been  prepa r e d  by  chemical  conjuga tion  with  essential  nutrient s  such  as
ascorbic  acid  (AA),  glucose  and  galactose .
Esterification  with  AA  is  carried  out  by  a  general  coupling  procedu r e
involving  a  protec t ed  precursor ,  the  2,3- diBn  derivative  of  AA, in  the  presenc e  of
N ,N’ -dicyclohexylcarbodiimide  (DCC),  leading  to  28  (Schem e  4).  Since  BrAA  is
endowed  with  bet te r  SVCT2  affinity  than  that  of  AA, BrAA  derivatives  of  KYNA
were  prepa re d  as  second- genera t ion  compounds .  The  coupling  between  BrAA
and  8  in  the  presence  of  DCC  resulted  in  30  (Schem e  4).  The  6- O-ascorba t e s  28
and  30  were  then  deprotec t e d  by  hydrogenolysis,  affording  the  desired  KYNA




















































Sch e m e  4.  Reagen t s  and  conditions:  i) DMAP,  DCC,  CH 2Cl 2  or  CH 2Cl 2/DMF;  ii)
TFA,  CH 2Cl 2,  then  H 2, C/Pd  10%,  MeOH
Esterification  of  9  with  1,2:4,5- di-O -isopropylidene-   - D-glucofuranose ,
1,2:3,4- di-O-isopropylidene-   - D-galactopyra nos e  and  1,2,  3,4- O-
tet ram e t hylca r bon a t e- D-glucopyranos e ,  in  the  presence  of  1,1’-
carbonyldiimidazole  (CDI)  furnished  32 ,  34  and  36  (Schem e  5).  The  Bn  group
was  cleaved  off  by  hydrogenolysis  and  the  protec ting  groups  of  the  resul tan t





















































































Sch e m e  5.  Reagen t s  and  conditions:  i) CDI,  CH 2Cl 2, DMF;  ii) TFA,  CH 2Cl 2,  then
H 2 , C/Pd  10%,  MeOH  
The  free  carboxylic  function  at  C-2  in  KYNA  derivatives  provides  a  new
synthet ic  possibility:  transforma t ion  to  amide  derivatives  by  using  the
corresponding  amines.  The  stra tegy  of  choosing  amines  follows  that  for  ester
formation,  e.g.  by  using  differen t  “natu ra l- like”  amines,  the  BBB  can  be
overcome.
The  amidation  of  KYNA  (4a )  with  glucosamine  (GLUC)  in  the  presence  of
1-hydroxybenzo t r iazole  (1-HOBT)  and  DCC  led  to  the  formation  of  38  (Scheme
6)  [26].
As  iminosuga r s  are  known  to  be  inhibitors  of  many  carbohydra t e-
processing  enzymes  and  to  exhibit  various  biological  activities,  a  series  of
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iminosuga r  core  structu r e s  were  const ruc t e d  and  (without  any  purification)  were
screene d  direc tly  agains t  tumor  cell  lines.  Among  these  compounds ,  39  and  40 ,
were  synthe t ized  and  tested  as  new  KYNA derivatives  (Schem e  6)  [27].
When  N -glycyl-   - glycopyranosylamine  was  reacted  with  4a  in  the  presence
of  DCC  and  N -hydroxysuccinimide  in  DMSO,  41  (Schem e  6)  was  isolated  [28].
A furthe r  extension  of  this  type  of  amidation  of  KYNA  involves  the  use  of
iminocyclitol  as  amine  componen t .  The  coupling  reaction  is  performe d  with  DCC








































































R1 = H, R2 = CH2OH: 39






Sch e m e  6.  Reagen t s  and  conditions:  i) DCC,  1-HOBT,  DMF;  ii) HBTU,  DIEA,
DMF;  iii) DCC,  N -hydroxysuccinimide,  DMSO
On  the  other  hand,  4a  provided  a  new  stra tegy  via  which  to  synthe t ize  new
asymmet r ic  monohydroxyethylene  (43  and  45 )  or  symmetr ic  (44  and  46 )
peptidomime t ics  as  potential  HIV-1  [30]  and  C.  albicans  aspar t ic  [31]  protea se

































































































































Sche m e  7.  Reagen t s  and  conditions:  i) DCC,  1-HOBT,  DMF  
The  syntheses  of  some  new  amides  of  KYNA  were  recently  repor t ed .  The
intensified  interes t  in  these  types  of  compounds  is  demons t r a t e d  by  the  number
of  paten t s  that  have  appea re d  in  this  field.  New  KYNA  amides  containing  a
substi tu t e d  piperidine  amide  moiety  at  C-2  (47- 57 ) have  been  prepa r e d  through
coupling  of  the  corresponding  KYNA  derivatives  with  the  amines,  O-
(benzotr iazol- 1-yl)-N,N,N ,N′ ′ -tetra m e t hylu ronium  hexafluorophosp h a t e  (HBTU)
serving  as  coupling  agent  [12,13].
A  new  series  of  KYNA  amides  bearing  a  substi tu t ed  piperazine  moiety
following  the  double  amide  function  (58 , Schem e  8)  were  succesfully  synthe t ized
in  DMF  in  the  presence  of  1-HOBT  and  3-dimethylaminop ropyl- 3-
ethylcarbodiimide  (EDCI)  [32].  60 ,  a  4-substi tu t ed  analog  of  58 ,  was  obtained  in
two  differen t  pathways:  transform a t ion  of  the  OH  group  of  KYNA derivatives  to
OR 6  by  the  standa r d  Williamson  synthesis ,  followed  by  coupling  with  the
corresponding  amines,  or  applica tion  of  the  Williamson  synthesis  to  amide  58 ,
leading  to  60  (Schem e  8)  [32].
-13 -
Another  subgroup  of  KYNA  amides  bearing  a  wate r- soluble  side- chain  in












R1=H, Y=CH2, Z=H: 47
R1=7-OH, Y=CH2, Z=H: 48
R1=6-OH, Y=CH2, Z=H: 49
R1=6-OH, Y=CH2, Z=F: 50
R1=6-OH, Y=CH2, Z=Cl: 51
R1=6-OH, Y=CH2, Z=Me: 52
R1=6-OH, Y=O, Z=H: 53
R1=6-OH, Y=O, Z=Cl: 54
R1=6-OH, Y=O, Z=Me: 55
R1=6-AcNH, Y=CH2, Z=H: 56
































































Sch e m e  8.  Reagen t s  and  conditions:  i) H 2, 10%  Pd/C,  MeOH,  rt;  ii) Ac2O,  reflux;
iii) NaOH,  MeOH,  H 2O,  rt,  then  HCl;  iv ) 1-HOBT,  EDCI;  DMF;  v ) HBTU,  Et 3N,
DMF;  vi ) R6X, Cs 2CO 3, DMF
In  order  to  obtain  the  carbonylamino te t r azole  derivative  62 ,  an  activated
2,4,6- trichlorophe nyl  ester  (61 )  was  first  isolated,  which  was  then  reacted  with





















Sche m e  9.  Reagen t s  and  conditions:  i) NaOH/MeO H,  reflux,  2h;  ii) SOCl 2, rt,
overnigh t;  iii) 2,4,6- trichlorophe nol ,  pyridine,  toluene,  3h;  iv ) aminote t r azole
monohydra t e ,  Et 3N,  acetone,  reflux
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The  prepa r a t ion  and  transforma t ion  of  a  hydrazide- type  moiety  in  the  side-
chain  led  to  new  KYNA  derivatives.  When  KYNA  methyl  ester s  3b , 6 , 10- 12
were  trea te d  with  guanidine  in  DMF,  63- 66  were  formed  (Schem e  10)  [14].
Following  the  reaction  of  6-F-KYNA methyl  ester  (3b )  with  semicarb azide ,
67  (Schem e  10)  was  isolated  [14].
Hydrazide  derivatives  68  and  69  were  prepa r e d  from  3b  and  10  by
trea tm e n t  with  hydrazine  hydra t e ,  and  were  subseque n t ly  guanyla ted  with  1 H -
pyrazole- 1-carboxamide  to  give  70  and  71  (Schem e  10)  [14,15].
i
X=F, Y=H, R=OH: 3b
X=F, Y=H, R=Cl: 6
X=F, Y=H, R=OEt: 10





























X=F, Y=H, R=Cl: 63
X=F, Y=H, R=OEt: 64























Sche m e  10.  Reagen t s  and  conditions:  i) guanidine ,  DMF,  rt,  then  EtOH/HCl  or
HCl  aq.  (10%);  ii) semicarbazide,  DMF/dioxane;  iii) NH 2NH 2, 1.5  H 2O,  reflux,  2  h;
iv ) 1 H -pyrazole- 1-carboxamide  hydrochloride ,  DMF,  100  °C,  3  h
The  ring  closure  of  68  with  triphosge n e  led  to  8- fluoro- 4-hydroxy- 1 H -
[1,2,4]t riazino[4,5- a ]quinoline- 1,6(2H)- dione  (72 )  [15].  Alkylation  of  72  with  2
equivalents  of  K2CO 3  and  ethyl  bromoace t a t e  resul ted  in  double  alkylation
(Schem e  11,  73 ) without  any  trace  of  monoalkyla ted  compound.
In  contras t ,  a  Michael  addition  with  methyl  acryla te  in  the  presence  of
Et 3N  led  to  the  selec tive  introduc tion  of  a  methyl  propanoa t e  group  onto  N-2
(Schem e  11,  74 ) [15].
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Regioselec tive  alkylation  on  N-2  occur red  upon  react ion  with  EtI  in  the
presence  of  NaH  as  base  (Scheme  11,  75 ) [15].
As  a  furthe r  transform a t ion ,  [1,2,4]t riazino  compound  72 ,  was  chlorina t ed
with  POCl 3,  yielding  76 .  In  order  to  ascer t a in  the  position  of  the  Cl  substi tue n t ,
76  was  subsequ e n t ly  reduced  by  catalytic  hydrogena t ion  under  pressur e ,






































































Sch e m e  11.  Reagen t s  and  conditions:  i) triphosge n e ,  Py,  CH 2Cl 2; ii) ethyl
bromoace t a t e ,  K2CO 3 , DMF,  50  °C;  iii) methyl  acrylate ,  Et 3N,  DMF,  100  °C;  iv )
EtI,  NaH,  DMF;  v ) POCl 3 , reflux;  vi ) Pd- C (10%),  H 2, DMF
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3.  Pharm a c o l o g i c a l  activi t i e s  of  KYNA  derivat ive s
It  is  well  known  that  KYNA  has  neuroac t ive  proper t ies  (reviewed  in
[3,5,9]).  It  is  synthesized  from  L-KYN  in  reactions  media ted  by  mitochondr ia l
aspar t a t e  aminot r ansfe r a s e  [35]  and  kynurenine  aminotr ansfe r a s e s  (KATs):  KAT-
I,  KAT-II  [36- 38]  and  KAT-III  [39]  in  astrocytes ,  glial  cells  [40]  and  neurons  [41].
The  larges t  amount  of  KYNA  is  produced  by  KAT  II  in  the  rat  [36].  Less
information  is  available  concerning  the  role  of  KYNA in  the  periphe ry  than  in  the
central  nervous  system  (CNS).  Recent  data  indicate  that  major  amounts  of
serum  KYNA are  produced  and  libera t ed  from  the  vascula r  endothelium  [42,43].
KYNA displays  a  broad  spect ru m  of  antagonis t ic  prope r t i es .  In  the  human
cerebros pinal  fluid  (CSF),  the  concen t r a t ion  of  KYNA is  in  the  nanomolar  range
[44].  It  can  act  competi t ively,  primarily  at  the  strychnine- insensi tive  glycine-
binding  site  of  the  NMDA  recep to rs  [45- 47].  At  higher  concent r a t ion,  it  can
competi t ively  inhibit  the  AMPA  and  kainat e  recep to r s ,  too  [45,46,48,49].
Interes t ingly,  Prescot t  et  al.  [50]  repor t ed  that  KYNA  in  nanomolar  to
micromolar  concent r a t ions  is  able  to  facilita te  the  AMPA  recepto r  respons es .
However ,  the  concen t r a t ion  ranges  are  controve rsial ,  because  it  was  recently
demonst r a t e d  that  KYNA  in  micromolar  concent r a t ions  still  has  a
neuroinhibi tory  effect,  whereas  in  nanomola r  concen t r a t ions  it  behaves  as  a
facilita tor  [1].  Moreover ,  KYNA non- competi t ively  blocks  the    - 7-nACh  recepto rs
[51],  activation  of  which  at  the  presynap t ic  site  takes  par t  in  the  regula tion  of
glutama t e  release  [52],  and  hence  in  both  glutam a t e r g ic  and  cholinergic
neurot r a ns miss ion.  Furthe r m o r e ,  in  nanomolar  concen t r a t ions ,  acting  on    - 7-
nACh  recep to r s ,  it  can  reduce  the  extracellula r  level  of  dopamine  in  the  rat
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striatum.  This  fact  sugges t s  that  even  modes t  increase s  in  the  brain  KYNA level
can  contribute  to  modula tion  of  the  dopamine rgic  trans mission  [53].
GPR35,  which  is  a  G-protein- coupled  recepto r  in  immune  and
gast roin t es t inal  tissues ,  was  also  found  to  be  selec tively  activated  by  KYNA,  but
not  by  other  kynurenines  [54].
In  view  of  its  pharm acological  proper t i es ,  an  increase  of  the  level  of  KYNA
in  the  CNS  seems  to  be  a  potential  therape u t ic  stra tegy.  Howeve r ,  KYNA  can
cross  the  BBB  only  poorly  [55],  whereas  L-KYN is  transpo r t e d  across  much  more
easily  by  a  neutra l  amino  acid  carrie r  [55].  This  is  often  utilized  in  animal
models,  where  L-KYN  is  adminis te r e d  in  monothe r a py  or  in  combina tion  with
probenecid  to  elevate  the  KYNA concen t r a t ion  in  the  CNS.
However ,  an  excessive  elevation  of  the  KYNA  level  could  have  adverse
effects.  The  intrace r e b roven t r icula r  injection  of  KYNA  to  rats  resul ted  in
reduced  explora to ry  activity,  ataxia,  stereotypy,  sleeping  and  respira to ry
depress ion  (mainly  in  higher  doses),  while  there  was  only  a  slight  effect  on  the
learning  ability  [56].  The  precurso r  L-KYN did  not  exert  any  marked  effect  when
applied  in  equimolar  doses.  KYNA has  been  shown  to  be  an  anxiolytic  compound
[57],  while  L-KYN is  anxiogenic  [58].
In  conseque nc e  of  its  elevated  CNS  level,  KYNA behaves  as  an  endogenous
neurop ro tec t ive  agent  and  it  is  able  to  preven t  neuronal  loss  following
excitotoxic,  ischemia- induced,  and  infectious  neuronal  injuries  [10,11,59].  The
changed  level  of  KYNA  in  the  CNS  correla t es  with  several  disorder s
(summa rized  in  Table  2).  
KYNA  and  its  derivat ive s  under  patho l o g i c a l  condi t io n s  
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Many  reviews  have  been  published  on  the  relationships  betwee n  oxidative
stress ,  free  radicals,  neurological  diseases  and  the  metabolites  of  the  kynurenine
pathway  [60,61].  Stone  [23]  has  also  surveyed  the  therape u t ic  potential  of  the
neuroac tive  kynurenines  and  their  analogs.  Thus,  the  aim  of  this  chapte r  is  to
give  a  concise  overview  of  the  pharm acological  activity  of  the  base  molecule
KYNA,  concen t r a t ing  mainly  on  the  CNS,  and  to  consider  the  possible
therap e u t ic  significance  of  the  novel  KYNA derivatives  in  the  past  decade.
Table  2.  KYNA concen t r a t ions  under  pathological  conditions
Disorde rs Possible  changes  in  level  of  KYNA Referenc
es
Ischemia No  altera t ion  in  KYNA level  or  KAT activities [11]
Alzheimer’s
disease
A  slightly  elevated  KYNA  concen t r a t ion  in  the
putam en ,  cauda te  nucleus  and  hippocam p us  in




Lowered  KYNA  concen t r a t ions  in  the  frontal
cortex,  putame n  and  substan t i a  nigra  pars




A KYNA level  deficiency  and  decreas e d  activities
of  KAT-I and  KAT-II in  the  striatum  
[64,65]
An  imbalance  betwee n  the  levels  of  neuroac t ive





A lower  KYNA  level  in  the  CSF  in  patient s  with
stable  relapsing- remit ting  multiple  sclerosis  
[67]
An  increas e d  KYNA conten t  during  relapse  of  the
disease  
[68]
Epilepsy A decreas e d  KYNA  level  in  the  CSF  of  subjects
with  West  syndrome
[69]
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No  correla tion  between  the  developme n t  of
complex  partial  seizures  and  the  CSF  KYNA
concen t r a t ion
[70]
Schizophre nia An elevated  KYNA level  in  the  prefron ta l  cortex  [71]
An increase d  concen t r a t ion  of  KYNA in  the  CSF  [72]
Diabete s
mellitus
Elevated  KYNA  levels  in  senile  nuclear  human
cata rac t s  
[73]
Isch e m i a
The  excitotoxicity  caused  by  overexcita t ion  of  the  glutama t e  recepto r s  is
known  to  play  an  impor tan t  role  in  brain  ischemia  [74].  It  was  recen tly
demonst r a t e d  that  KYN pret r ea t m e n t  prese rves  the  hippocam p al  pyramidal  cells
in  the  CA1  area  after  global  ischemia  in  gerbils  and  reduces  the  focal  infarc tion
in  mice  [10].  In  very  high  doses  (400- 1800  mg/kg  b.w.),  KYNA can  cross  the  BBB
and  induce  an  increase  in  the  KYNA  level  of  the  CNS.  This  increas e d
concen t r a t ion  exert s  a  neurop ro tec t ive  effect  after  bilate ral  carotid  occlusion  in
transien t  forebra in  ischemia  in  gerbils  [75].  Periphe r a lly  adminis te r e d  L-KYN,
which  causes  an  increas ed  KYNA level  in  the  brain,  increas es  the  normal  and  the
unilate r a l  carotid  artery  occlusion- induced  ischemic  corticoce reb r a l  blood  flow
in  conscious  rabbits  [76].  It  has  been  repor t ed  that  L-KYN  adminis t r a t ion  can
mitigat e  the  delayed  cortical  neuronal  damage  in  an  animal  model  of  transien t
global  ischemia  [77].  In  the  four- vessel  occlusion  model  in  the  rat,  combined
trea tm e n t  with  L-KYN  and  probenecid  proved  able  to  rescue  the  Schaffer
collater a l- CA1  synapses  from  impaired  long  term  potentia t ion  induction  after
transien t  global  ischemia  [78].  Taken  togethe r ,  these  findings  sugges t  that  an
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increase d  concen t r a t ion  of  KYNA  has  an  impor tan t  modula ting  role  in  the
neuronal  cell  damage  after  ischemic  conditions.  
Neur o d e g e n e r a t i v e  diso r d e r s   (Alzheim er’s  disease,  Parkinson’s  disease,
Huntington’s  disease  and  multiple  sclerosis)
The  ratio  TRP/L- KYN in  the  plasma  is  elevated  in  Alzheimer’s  disease  [79],
as  an  indication  of  the  importance  of  the  kynurenine  pathway  in  this  disorde r .
An  increas e d  KYNA  level  has  been  demonst r a t e d  in  the  putam en  and  cauda te
nucleus  of  Alzheimer’s  disease  patient s ,  accompa nied  by  significant  increas es  in
KAT I activity  in  both  nuclei  [62].
The  ratio  TRP/L- KYN  is  decreas e d  in  both  the  serum  and  the  CSF  of
patient s  with  Parkinson’s  disease  as  compare d  with  normal  controls  [80].
Lowered  KYNA  concen t r a t ions  have  been  measu re d  in  the  frontal  cortex,
putam en  and  substan tia  nigra  pars  compac t a  of  such  patient s  [63].  The  bilater al
injection  of  5,7- di-Cl-KYNA  (4f )  into  the  rost ral  striatum  inhibited  the
haloperidol- induced  muscle  rigidity  in  the  model  of  parkinsonian- like  muscle
rigidity  in  the  rat  [81].
A decreas e d  KYNA level  and  a  reduced  activity  of  KAT have  been  found  in
the  striatum  of  Huntington’s  disease  patient s  [64,65];  these  altera t ions  are
sugges t e d  to  be  related  to  the  developm e n t  of  the  condition.  An  imbalance  of
this  disease  has  also  been  demons t r a t e d  between  the  levels  of  neuroac t ive
kynurenines  in  the  stria tum  in  the  differen t  stages  [66],  with  a  slight  striatal
KYNA elevation  in  the  early  stages  and  a  decreas e d  or  normal  concen t r a t ion  in
the  advanced  stages .  The  ratio  TRP/L- KYN is  lower  in  subject s  with  Hunting ton’s
disease  than  in  healthy  controls.  The  higher  levels  of  L-KYN  in  such  patient s  do
not  resul t  in  any  differences  in  KYNA levels  in  an  advanced  stage,  providing  no
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evidence  of  endogenous  neuropro t ec t ive  compens a t ion  by  KYNA  [82].
Intras t r i a t al  injections  of  QUIN  cause  significantly  larger  lesions  in  mice  with  a
targe t e d  deletion  of  KAT II  than  in  wild- type  animals,  which  indicates  that  KYNA
controls  the  vulnerabili ty  of  the  striatal  neurons  to  QUIN  [83].  These  data
demonst r a t e  abnorm ali t ies  in  the  kynurenine  pathway  which  may  play  a  role  in
the  pathom ec h a n is m  of  Huntington’s  disease .
Lower  KYNA  levels  have  been  found  in  the  CSF  in  patient s  with  stable
relapsing- remit ting  multiple  sclerosis  as  compared  with  heal thy  controls  [67].
Recent  findings  indicate  an  increas ed  KYNA  conten t  during  the  relapse  of  the
disease  [68],  when  immune  cells  are  presum e d  to  be  abunda n t  in  the  CNS,
catabolizing  TRP  to  produce  L-KYN  metabolit es .  In  the  periphe ry,  the
erythrocytes  of  multiple  sclerosis  patient s  display  increase d  levels  of  KAT I  and
II  [84],  sugges t ing  the  presence  of  genera l  activation  mechanis ms  in  the  disease
affecting  the  CNS.  However ,  stable  multiple  sclerosis  patient s  did  not  exhibit
significant  changes  in  the  plasma  KYNA concen t r a t ion  during  24  h  of  monitoring
[85].
Epile p s y
Combined  L-KYN  and  probenecid  administ r a t ion,  which  elevate s  the  CNS
KYNA  level,  attenu a t e s  pentylene t e t r a zole- induced  seizure s  in  the  rat  brain
[86,87].  In  WAG/Rij  rats,  which  are  a  genetic  model  of  absence  epilepsy,  the
KYNA  levels  are  significantly  lower  in  the  frontal  lobe  [88],  sugges t ing  its
involvement  in  the  higher  excitability.  Scharfman  et  al.  [89]  showed  that,
following  the  bath- applica tion  of  L-KYN,  de  novo  synthet ized  KYNA  is  much
more  effective  than  normally- synthe t ized  KYNA  agains t  low  extracellula r
magnesium- induced  spontaneous  epileptiform  activity.  In  vitro  studies  have
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indicated  that  many  antiepilept ic  drugs  enhance  KYNA production  in  rat  cortical
slices,  pointing  to  an  alterna t ive  targe t  of  such  medica tion  [90].  
Magnesium- induced  seizures  were  successfully  attenu a t e d  by  7-Cl-KYNA
(4i )  applied  in  vitro  to  hippocam p al  and  entorhinal  cortical  slices  [91].  In
pilocarpine- induced  epilepsy,  an  enhanced  7-Cl-KYNA  concen t r a t ion  and  a
higher  extracellular  KYNA  level  were  detec ted  by  an  in  vivo  microdialysis
technique.  Furthe r m o r e ,  in  vitro  studies  (tissue  slices)  have  revealed  an
enhance d  synthesis  of  both  KYNA and  7-Cl-KYNA (4i)  in  the  same  area.  This  may
sugges t  that  the  brain  can  synthesize  the  NMDA  recep to r  antagonis t  under
pathological  conditions  [92].  Battaglia  et  al.  [93]  repor t ed  that  D-glucose  or  D-
galactose  este rs  of  7-Cl-KYNA  (33 ,35  and  37 )  readily  cross  the  BBB  and  are
conver te d  to  7-Cl-KYNA or  KYNA by  astrocyte s  and  neurons  in  the  brain.  These
data  indicate  that  the  glucose- conjuga te  may  have  a  role  in  transpor t ing  drugs
across  the  BBB.  At  the  same  dose,  glucose- conjuga ted  ester s  exhibited
neurop ro tec t ive  effects  agains t  NMDA  toxicity  and  epileptic  seizures .  
In  an  in  vitro  study,  mice  were  pret r ea t e d  with  7-Cl-KYNA (4i)  or  one  of  its
ester s  (33 ,35  and  37 ) before  NMDA  injection.  The  NMDA- induced  seizures  were
not  mitigated  in  the  animals  injected  with  7-Cl-KYNA (4i )  and  ester  35 .  It  was
hypothesized  that  35  could  not  pene t r a t e  successfully  through  the  BBB.  Ester s
33  and  37 , in  the  same  dose,  did  attenu a t e  NMDA- induced  seizures  in  mice  [19].
Both  in  vivo  and  in  vitro  experimen t s  sugges t  that  37  may  be  of  poten tial  in  the
therapy  of  epilepsy.
Systemic  adminis t ra t ion  of  a  newly  synthe t ized  compound,  GLUC–KYNA
(38 ),  which  readily  pene t r a t e s  the  BBB,  leads  to  an  increase d  KYNA
concen t r a t ion  in  the  CNS  [94].  Intrace r e b rove n t r icula r ly  adminis te r ed  GLUC–
KYNA (38 ) induces  the  same  behavioral  effects  in  rats  as  those  of  KYNA [26].  In
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elect rophysiological  experime n t s ,  intravenously  injected  GLUC–KYNA  ( 38 )
decreas e d  the  amplitudes  of  the  bar rel  field  potentials  evoked  by  contrala te r a l
whisker  pad  stimula tion.  GLUC–KYNA  (38 )  in  a  lower  dose  significan tly
decreas e d  the  amplitude  of  the  cortical  responses  relative  to  those  of  KYNA
(given  intravenously  in  the  same  dose;)  [26].  In  in  vivo  experimen t s ,  systemically
adminis te r e d  GLUC–KYNA  (38 ),  but  not  pure  KYNA,  mitigated  the  evoked
activity  in  the  hippocam p al  CA1  area  [94].  
Administ ra t ion  of  5,7- di-Cl-KYNA  (4f )  into  the  hilus  of  the  gyrus  denta t e
preven te d  both  the  behavioral  and  the  elect rogr a p h ic  manifes ta t ions  of  status
epilepticus  [95].  In  animal  experime n t s  5,7- di-Cl-KYNA  ( 4f )  suppress e d  both
glutama t e-  and  glycine- induced  seizures  [96].  When  the  neurop ro tec t ive  effects
of  4- trans -2-carboxy- 5,7- dichloro- 4-phenylaminoca rbo nyla mino- 1,2,3,4-
tet rahydroq uinoline  (L-689,560),  5,7- di-Cl-KYNA  (4f )  and  7-Cl-KYNA (4i )  were
tested  on  a  primary  culture  of  rat  cortical  neurons,  all  afforded  protec tion
agains t  glutam a t e- induced  excitotoxicity  [97].  
Recent  findings  demons t r a t e d  that  9  of  12  4-urea- 5,7- di-Cl-KYNA
derivatives  tested  exerted  anticonvulsan t  activity  in  mice  in  maximal
elect roshock,  subcutan eo us  pentylene t e t r azole  and  threshold  tonic  extension
tests  [25].  The  methyl  ester  of  diphenylure ido- di-Cl-KYNA  appea re d  to  be
protect ive  against  audiogenic  seizures  in  DBA/2  mice  [18].
While  epilepsy  seems  to  be  the  most  widely  examined  pathological
condition  in  relation  to  kynurenine  pathway,  several  derivatives  of  KYNA  have
been  tested  in  experimen t a l  models  in  the  last  decade,  too,  giving  the  possibility
of  studying  the  structu r e- activity  relationship  (Table  3).
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Table  3.  The  pharma cological  activity  of  the  systemically  administe r e d  KYNA
derivatives  in  the  experime n t a l  models  of  epilepsy
Derivatives Pharm acological  activity Referenc
es
4i The  NMDA- induced  seizures  were  not  mitigated .
[19]
35
33 The  NMDA- induced  seizures  were  attenua t e d
(probably  due  to  bet te r  BBB penet r a t ion).
37
38 A  great e r  decreas e  in  the  amplitude  of  the
cortical  response s  relative  to  KYNA.
[26]
38 Mitigated  the  evoked  activity  in  the  hippocam p al
CA1  area  (but  not  KYNA).
[94]
Migra i n e
Migraine  has  a  complex  pathophysiology  in  which  both  centra l  and
periphe ra l  componen t s  of  the  trigeminal  pain  pathway  probably  play  significan t
parts .  The  role  of  glutam a t e  is  strongly  indicated  at  differen t  sites  of  migraine
pathogen e s i s  [98].  In  one  animal  model  of  trigeminovascula r  activation  after
elect rical  stimula t ion  of  the  Gasser ian  ganglion,  decreas e d  KAT expression  was
observed  among  the  dural  Schwann  cells  [99].  In  combina tion  with  probenecid,
L-KYN  is  able  to  reduce  c-fos  activation  in  the  caudal  trigeminal  nucleus  in  the
above  model  [100].  The  periaque d uc t a l  grey  cell  activity  involved  in  nociception
can  also  be  altered  by  the  adminis t r a t ion  of  KYNA [101].  These  findings  sugges t
that  kynurenines  can  influence  the  brain  stem  structu r e s  involved  in  the
pathogen e s i s  of  migraine.
In  one  migraine  model,  SZR72,  is  a  novel  synthe t ic  KYNA  analog,
significantly  attenua t e d  the  nitroglycerine- induced  increase  in  the  number  of  c-
fos -immunorea c t ive  neurons  in  the  caudal  trigeminal  nucleus  in  the  rat  [33].
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Such  findings  sugges t  the  influence  of  the  kynurenine  pathway  on  a  wide  range
of  neurons  involved  in  the  process .
Pain  
It  has  been  repor t ed  that  NMDA  recepto r s  play  an  import an t  par t  in  spinal
nocicep tive  transmission  [102- 104].  The  periphe r a l  role  of  the  metaboli tes  of  the
kynurenine  pathway  in  pain  processing  was  postula te d  by  Simone  et  al.  [105].
Iontophoric  administ r a t ion  of  KYNA  to  the  spinal  cord  reduces  the  nocicep to r
response  of  the  spinal  cord  neurons  after  cutaneous  and  muscula r  noxious
stimulat ion  [106].
Microinjec tions  of  KYNA  or  7-Cl-KYNA (4i )  signi cantly  inhibit  theﬁ
acquisition  of  formalin- induced  conditioned  place  avoidance  (CPA)  without
reducing  electric  foot- shock  CPA  and  acute  formalin- induced  nociceptive
behavior  in  rats  [107,108].  In  vitro  elect rophysiological  examina tions
demonst r a t e d  that  NMDA- evoked  curren t s ,  but  not  formalin- induced  nociceptive
behavior,  were  successfully  inhibited  by  7-Cl-KYNA (4i )  in  rost ral  ante rior
cingula te  cortex  slices  [108].
Animal  investiga t ions  sugges t  that  5,7- di-Cl-KYNA  (4f )  can  inhibit
intraplan ta r  formalin- induced  nocifensive  behavior  and  tissue  injury  in  a  dose-
depend en t  manne r  without  any  side- effects  [109].  At  a  dose  of  46.4  mg/kg
bodyweigh t  (i.p.),  it  reduced  the  pain  score  by  approximat ely  88%  as  compare d
with  the  control  group.  It  also  inhibited  tactile  allodynia  in  a  neuropa t h ic  pain
model  in  the  rat .
Diphenylureido- di-Cl-KYNA  (21 ) was  synthet ized  with  a  view  to  achieving  a
combina tion  of  the  effects  of  carba m az epine  and  KYNA.  Diphenylureido- di-Cl-
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KYNA  (21 )  and  its  derivatives  (22  and  23 ),  which  easily  cross  the  BBB,  inhibit
both  NMDA  channels  at  the  strychnine- insensi tive  glycine  binding  site  and
sodium  channels.  Diphenylure ido- di-Cl-KYNA  (21 )  and  its  methyl  este r
diminished  glutama t e- induced  excitotoxic  cell  death  in  primary  cultures  of
cerebella r  granule  cells.  The  ethyl  ester  of  diphenylure ido- di-Cl-KYNA  ( 21 )
attenua t e d  tactile  and  therm al  hyperalgesia  in  animals  following  spinal  nerve
ligation,  and  in  C57BL/6  mice  exerted  an  anxiolytic  effect  in  the  elevated- plus
maze  test  [18].  Taken  togethe r ,  these  observa t ions  point  to  the  involvement  of
metaboli tes  of  the  kynurenine  pathway  at  various  sites  of  nocicep tion.
Schi z o p h r e n i a
An  elevated  KYNA  level  has  been  detecte d  in  the  prefronta l  cortex  of
schizophrenic  patient s  [71],  and  the  concen t r a t ion  of  KYNA has  also  been  found
to  be  increas e d  in  the  CSF  of  such  patient s  [72].  The  enhance d  brain  KYNA level
gives  rise  to  elect rophysiological  effects  [110- 112],  similarly  as  observed  after
NMDA  recepto r  adminis t r a t ion  [113].  These  findings  are  in  good  accordanc e
with  the  glutama t e r g ic  hypofunc tion  seen  in  schizophrenia  [114],  which  can
manifes t  in  an  elevated  firing  activity  of  midbrain  dopamine r gic  neurons  via
inhibition  of  the  tonic  GABAergic  input,  which  normally  dampens  the  neuronal
activity  [111].
The  neurobiological  backgroun d  of  the  sensory  gating  deficits  in
schizophrenia  is  not  fully  unders tood.  An  elevated  KYNA  level  in  rats  has  been
repor t ed  to  be  associa ted  with  an  altered  responsivenes s  to  auditory  stimuli,
caused  by  an  interac t ion  with  the    - 7-nACh  recep to r  [115].
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Ret in a l  da m a g e
KYNA and  KAT activities  have  been  observed  in  mamm alian  eyes  [116].  In
the  retina  of  DBA/2J  mice,  the  impairme n t  of  KYNA  biosynthesi s  that  is
demonst r a t e d  may  be  one  of  the  mechanis ms  of  retinal  degene r a t ion  related  to
ocular  hyper t ension  [117].  A dysfunction  of  the  glutama t e r g ic  system  has  been
described  in  various  pathological  conditions  in  the  retina,  e.g.  retinal  damage
such  as  glaucoma  [118]  and  optic  neuropa t hy  [119].  Interes t ingly,  KYNA  level
changes  have  been  observed  in  both  the  rat  and  the  chicken  retina  during
ontogeny  [120].
In  vivo  experime n t a l  data  have  revealed  that  5,7- di-Cl-KYNA  (4f )  inhibits
NMDA- induced  cell  loss  in  the  retinal  ganglion  cells,  thinning  of  the  inner
plexiform  layer,  and  the  occur re nc e  of  DNA  fragmen t a t ion  revealed  by  terminal
deoxynucleotidyl  transfer a s e- media t ed  dUTP  nick  end- labeling  (TUNEL).  These
findings  sugges t  that  glycine  site  stimula t ion  by  endogenous  ligands  is
obligatory  for  NMDA- induced  retinal  damage  [121].
Diab e t e s  mel l i t u s
Change d  levels  of  kynurenines  may  play  an  import an t  role  in  diabet ic
cata rac t  [122].  Kynurenines  and  their  glycoside  derivatives  in  the  ocular  lens
absorb  ultraviolet  radia tion  and  thereby  possibly  help  protec t  the  retina  from
ultraviolet  light.  Elevated  KYNA  levels  have  been  repor t ed  in  senile  nuclear
human  catarac t s  and  in  catar ac tous  lenses  of  rats  with  experime n t a l ly  induced
diabete s  [73].
In  rats  with  diabete s  mellitus  of  type  II,  the  glucose  concent r a t ions  have
been  measu re d  in  the  plasma.  Variation  of  the  differen t  groups  at  position  4  ( 5 ,
-28 -
6 ,  10 -12 ),  did  not  cause  an  increase  in  the  hypoglycemic  activity  [14].  A
carbonylgua nidine  group  at  position  2  (66 )  enhance d  hypoglycemic  activity  as
compare d  with  one  of  position  3  [14].
Hyp er t e n s i o n
The  rost ral  ventrola te r a l  medulla  plays  an  impor tan t  role  in  regula t ion  of
the  arte rial  blood  pressur e .  Injection  of  KYNA  into  this  organ  in  spontaneously
hyper t ensive  rats  decreas e d  the  mean  arter ial  pressure ,  whereas  this  effect  was
not  observed  in  Wistar- Kyoto  rats  [123].
3.  Conclu s i o n s  and  outlo ok
The  evidence  indicate s  that  KYNA and  its  derivatives  play  crucial  roles  in
maintaining  the  normal  brain  function.
Animal  studies  have  demons t r a t e d  that  elevated  levels  of  KYNA  or  KYNA
derivatives  in  the  brain  may  reduce  the  overac tivation  of  excita tory  amino  acid
recep to rs  and  thereby  modify  or  arres t  the  progress ion  of  various  disorde r s .  In
view  of  structu r e- activity  relationship,  there  are  only  few  available  data
reflec ting  the  advances  in  systema t ic  drug  design  in  the  past  decade.  While  the
earlier  attempt s  mainly  focused  on  enhancing  the  potency  (e.g.  subs ti tu t ion  with
halogen  atoms),  the  recent  activities  par ticula rly  deal  with  the  conversion  of  the
2-carboxylic  function  to  the  pharm acologically  interes t ing  derivatives  of  KYNA.
This  can  offer  a  novel  therape u t ic  oppor tuni ty,  and  the  developme n t  of  these
powerful  new  compounds  promises  to  be  the  key  to  brain  neurop ro t ec t ion.
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